DOCSLIB.ORG

Appendix B €C Gf

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Appendix B €C Gf Appendix B €C § Gf M Ameiucan Medical Association 535 NORTH DEARBORN STREET • CHICAGO. ILLIMOIS 60610 • PHONE (312) 751-6000 • TWX 910-221 0300 JAMMONS. M 0. tiecul'** Rreiidont (751 6200) September 3, 1981 Arthur Hull Hayes, Jr., M.D. Commissioner of Foods and Drugs 5600 Fishers Lane Rockville, Maryland 20857 RE: ■ Policy on Combination Prescription Drugs r* r r C-. oon irn Dear Commissioner Hayes: As v/e communicated to Secretary Schweiker in our letter of June 23, 1981, attached, the Amierican Medical Association is on record as agreeing that controlled clinical studies represent the best method of assessing drug efficacy and safety. We also believe, hoivever, that the accumulated experience of practitioners should be taken into account in determining the efficacy of drugs that have a long record (Df successful use in medical practice. This policy position is particularly applicable to combination prescription drugs where controlled studies may often be difficult, very coscly, and time-consuming to perform and evaluate. We recognize the difficulties faced by FDA in making final decisions about the continued marketability of the hundreds of combination drugs in the Drug Efficacy Study Implementation (DESI). In our view, it is n(3t always necessary for-FDA to insist on the conduct ot controlled clinical studies to provide "adequate evidence of effectiveness for such products. Instead, we believe FDA should evaluate all appropriate indices of efficacy -- including pnysician experience. To this end, "^he Am.erican Medical Association has prepared the attached suggested "Policy on Combination Prescription Drugs" which 'we urge the Agency to incorporate in its implementation of tlie existing regulation at 21 C.F.R. Sec. 300.50. As we conclude in this document. 000019 Dr. Hayes September 3, 1981 Page 2 which will be included in our comprehensive submission to your Task Force on Regulatory Reli.ef, "such a policy would likely be more cost-effective than the current policy, yet would not sacrifice any increment of public safety." ■Your prompt consideration of this request for a modification of existing policy standards v/ill be appreciated, Sincerely, James H.'Gammons, n,D, JHSrww Enclosures POLICY ON COMBINATION PRESCRIPTION DRUGS Citation 21 C.F.R. Sec. 300.50. Description The regulations in effect state, in part, that (a) Two or more drugs nay be combined in a single dosage form when each, component makes a contribution to the claimed dosage of each component (amount, frequency, duration) is such that the combination is safe and effective for a significant patient popu lation requiring such concurrent therapy as .defined in the labeling for the drug. AMA Concerns As a result of 1962 amendments to the Federal Food, Drug, and Cosmetic Act, FDA has been conducting efficacy evaluations of pre-1962 drugs, including combination prescription drugs, in the Drug Efficacy Study Implementation (DESI) program. FDA has 'interpreted and applied Sec. 300.50 to require that data from "well-controlled" clinical ives- tigations be produced to demonstrate efficacy when the accumulated medical literature to date does not contain such data, Such testing of long-used combination' drugs is highly complex scientifically and very costly. If a manufacturer does not undertake such studies and provide such data to FDA, FDA has been acting to withdraw the combination product's New Drug Application and remove the drug from the market. Impact Nothing in FDA's regulations at il C.F.R. Sec. 300.50 requires the clinical study protocols that are very costly, as well as difficult to design and evaluate, that FDA has recjiuested in the DESI review of these combination drugs in recent months. It is within FDA discretion to evaluate each DESI combination prescription drug individually based on all appropriate indices of efficacy. 0^ ■ • ■' ■ ■ ■ , . , . NORTH AMERICAN CLINICAL DERMATOLOGIC SOCIETY ' ' EXECUTIVE OFFICES—510 COMMONWEALTH AVE., BOSTON, MASS. 02215 '.L (r /'/v. PROGRAM DIRECTOR AND VICE PRESIDENT PRESIDENT VICE PRESIDENT ROBERT J. McNAMARA, M.D. JOHN T. McCarthy, m.d. CHARLES I. BLACK. M.D. 2028 TELEGRAPH AVE. 115 E filsl SrnEET 5220 FLANDERS DR. BERKELEY. CA 94705 NEW YORK. N V. 10021 BATON ROUGE, LA 70809 SECRETARY GENERAL COriRESPOtll5INr. SECRETARY TREASURER ■ EDMUND F. FINNERTY. M.D. DAVID W. POLAN. JR.. M.D. ROBERT D. HUBBARD. M.D. 510 COMMONWEALTH AVE. 520 COMMONWEALTH AVE. " 420 COURT STREET BOSTON. MASS. 02215 nOSTQN. MASS 02215 UTICA. N.Y. 13502 May 12, 1982 Marion B. Sulzberger, M.D. Committee on Use of Topical Medications 1567 Maple Ave. Evansto'n, 111. 60201 Dear Doctor Sulzberger: We are writing to clearly state the opinion of our one hundred sixty-five members, all of whom are active practicing dermatologists, that the proposed removal of combination topical agents would be a medical disaster for two reason,s: 1) The undoubted efficacy of combination products would O lead dermatologists to continue prescribing them - the Patient bearing the cost of compounding. 2) Compounding would be uneven at best. It is the unusual pharmacist who has had any significant experience in accurate compounding. Again, the patient suffers. We would respectfully refer you to the Editorial "Ban the Balm" Cutis 27:446, May 1981 and the forthcoming June Editorial in the same journal. Curiously, the absence of combination products would increase dermatologists referrals and thus there is no selfish motive involved in condemning^this ill advised Federal action. Respectfully submi-^ed, ¥ J/n- // ^ ( ^phn T. McCarthy, M.D. President Edmund T. Finnerty, M.D.' / -.'iVl Secretary Gene.ral JTM;EPF;j y-,nc. ■v.OV. ' .n ^^;vv;. : June 1, 1982 Jurs 3, ' John T. McCarthy, ?^,D. President American Clinical Dermatologic Sociptv 115 E. 6lst Street " ^ .New York, NY 10021 • ■ EdEStnd P. Pinnerty, r./I,D, Secretary General North American Clinical Dermatologic Society 510 Commonwealth Avenue ^ Boston, Mass, 02215 i Dear Drs, McCarthy and Finnertyj Your letter of May 12, I982 v/aa forwarded to me -from the office of the American Academy of Dermatology and reached me last Friday. As chairman of the ad hoc committee, preparing a statement to the FDA on the proposed removal of ..topical anti-infective agents by the PDA, I wish ito express to you the great encouragement that • • - your letter has given us. .. " opportunity arises, please convev my thanks ^d the thanks of my committee to the members of the North American Clinical Dermatologic Society. I do not know whether we will he atle to succeed in having the FDA reverse its decision about the removal of topical anti-infectivGS and combinations of such topical agents* However, if we, as physicians v/ho in the best jjosition to observe the effects of the medications we prescribe, do not express our convictions when government agencies propose to ban medicaments v;e have found useful, our patients v/ill vQ those v/hb suffer the most. • ■ '.1 . • "*■ ' •• ' V'" - , - ' - 2 - The opinions of your 165 members who are active practitlonGrs of dermatology will constitute Strong support for our position. There is a meeting of representatives of our ad hoc committee tomorrow, and I shall read your letter to them. Thank you again for writing as you did. Sincerely yours, ^^srion E. Sulzberger, iVi.D, CO. Peyton E. Weary, M.D. QQQ02* COMBINATION DRUG QUESTIONNAIRE American Academy of Dermatology, 1567 Maple, Evanston, IL 60201 NOTE TO RESPONDENTS: For purposes of this survey the following definitions will apply: growth or,^ oro"t ®to kill other micro-organisms.by a micro-organism which has the capacity to inhibit the COMBINATION - a formulation containing more than one active ingredient. Usually a steroid in combination with an anti-infective which is inhibiting to baclerii, fungi, or yeast. FOR QUESTIONS 1-8 PLEASE CHECK THE APPROPRIATE LINE FOR YOUR RESPONSE TO EACH ITEM. 1. Do you prescribe topical antibiotic combination drugs? Yes (1) No (2) 2. If "yes,"-how frequently do you prescribe them? Daily (1) Frequently (2) Occasionally (3) ; Rarely (4) 3. Do you prescribe steroid-antibiotic combinations? Yes (1) No (2) 4. If "yes," how often do you prescribe them? Daily (1) Frequently (2) Occasionally (3) Rarely (4) 5. Do you prescribe topical steroid-antifungal combination drugs? Yes (1) No (2) If "y®s," how often do you prescribe them? Daily (1) Frequently (2) Occasionally (3) Rarely (4) 7. Do you prescribe topical steroid-antiyeast combinations? Yes Cl) No (2) 8. If "yes," how often do you prescribe them? Daily (1) Frequently (2) Occasionally (3) Rarely (4) JUNE^ this QUESTIONNAIRE TO THE ACADEMY OFFICE NOT LATER THAN (cont'd) 000026 Page 2 PLEASE INDICATE FOR EACH OF THE FOLLOWING CONDITIONS, WHICH TOPICAL ANTIBIOTIC OR STEROID- ANTI-INFECTIVE AGENTS THAT YOU PRESCRIBE. CHECK EACH TREATMENT THAT APPLIES. (1) ■ (2) (3) (4) I Topical Steroid Steroid Steroid Antibiotics Antibiotic Antiyeast Antifungal Combination Combination Combination Combination 9. Atopic Dermatitis (9-12) 10. Secondarily Infected Eczema (13-16) 11. Secondarily Infected Dermatosis (17-20) 12. Intertrigo (21-24) 13. Impetigo (25-28) 14. Folliculitis (29-32) 15. Sycosis Barbae (33-36) 16. Paronychia (37-40) 17. Pustular Eruption of Hands and Feet (41-44) 18. Hailey-Hailey Disease (45-48) 19. Perleche (49-52) 20. Diaper Rash (49-52) 21. Moniliasis (57-60) 22. Tinea Facei (61-64) 23. Tinea Cruris (65-68) 24. Tinea Capitis (69-72) 25. Tinea Corporis (73-76) 26. Tinea Pedis (77-80) 27. Contact Dermatitis (81-84) 28. Otitis Externa (85-88) 29. Acne (89-92) 30. Rosacea (93-96) N 31. Tinea Versicolor (97-100) 00Q02? (cont'd) Page 3 OTHER (PLEASE SPECIFY) PLEASE INDICATE HOW OFTEN YOU HAVE PRESCRIBED THE FOLLOWING COMBINATION DRUGS IN THE LAST YEAR. CHECK ONLY ONE FOR EACH ITEM. 1 . 2 3 4 Frequently Occasionally Rarely Never 32. Bacitracin-Neoraycin (101) 33. Cor-Tar-quin® (102) 34.
Load more

Recommended publications
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • A New Robust Technique for Testing of Glucocorticosteroids in Dogs and Horses Terry E
    Iowa State University Capstones, Theses and Retrospective Theses and Dissertations Dissertations 2007 A new robust technique for testing of glucocorticosteroids in dogs and horses Terry E. Webster Iowa State University Follow this and additional works at: https://lib.dr.iastate.edu/rtd Part of the Veterinary Toxicology and Pharmacology Commons Recommended Citation Webster, Terry E., "A new robust technique for testing of glucocorticosteroids in dogs and horses" (2007). Retrospective Theses and Dissertations. 15029. https://lib.dr.iastate.edu/rtd/15029 This Thesis is brought to you for free and open access by the Iowa State University Capstones, Theses and Dissertations at Iowa State University Digital Repository. It has been accepted for inclusion in Retrospective Theses and Dissertations by an authorized administrator of Iowa State University Digital Repository. For more information, please contact [email protected]. A new robust technique for testing of glucocorticosteroids in dogs and horses by Terry E. Webster A thesis submitted to the graduate faculty in partial fulfillment of the requirements for the degree of MASTER OF SCIENCE Major: Toxicology Program o f Study Committee: Walter G. Hyde, Major Professor Steve Ensley Thomas Isenhart Iowa State University Ames, Iowa 2007 Copyright © Terry Edward Webster, 2007. All rights reserved UMI Number: 1446027 Copyright 2007 by Webster, Terry E. All rights reserved. UMI Microform 1446027 Copyright 2007 by ProQuest Information and Learning Company. All rights reserved. This microform edition is protected against unauthorized copying under Title 17, United States Code. ProQuest Information and Learning Company 300 North Zeeb Road P.O. Box 1346 Ann Arbor, MI 48106-1346 ii DEDICATION I want to dedicate this project to my wife, Jackie, and my children, Shauna, Luke and Jake for their patience and understanding without which this project would not have been possible.
    [Show full text]
  • Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1
    TITLE 16. CRIMES AND OFFENSES CHAPTER 13. CONTROLLED SUBSTANCES ARTICLE 1. GENERAL PROVISIONS § 16-13-1. Drug related objects (a) As used in this Code section, the term: (1) "Controlled substance" shall have the same meaning as defined in Article 2 of this chapter, relating to controlled substances. For the purposes of this Code section, the term "controlled substance" shall include marijuana as defined by paragraph (16) of Code Section 16-13-21. (2) "Dangerous drug" shall have the same meaning as defined in Article 3 of this chapter, relating to dangerous drugs. (3) "Drug related object" means any machine, instrument, tool, equipment, contrivance, or device which an average person would reasonably conclude is intended to be used for one or more of the following purposes: (A) To introduce into the human body any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (B) To enhance the effect on the human body of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (C) To conceal any quantity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; or (D) To test the strength, effectiveness, or purity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state. (4) "Knowingly" means having general knowledge that a machine, instrument, tool, item of equipment, contrivance, or device is a drug related object or having reasonable grounds to believe that any such object is or may, to an average person, appear to be a drug related object.
    [Show full text]
  • United States Patent (19) 11 4,360,518 Rovee Et Al
    United States Patent (19) 11 4,360,518 Rovee et al. 45) Nov. 23, 1982 54 TOPICAL ANTI-INFLAMMATORY DRUG Primary Examiner-Stanley J. Friedman THERAPY . 57) ABSTRACT 75) Inventors: David T. Rovee, Bridgewater; John A pharmaceutical composition for topical treatment of R. Marvel; James A. Mezick, both of cutaneous disorders or disruptions characterized by East Brunswick, all of N.J. skin inflammation or hyperproliferative epidermal ac 73) Assignee: Johnson & Johnson, New Brunswick, tivity comprises the combination of a topically active N.J. anti-inflammatory corticosteroid and a non-steroidal 21 Appl. No.: 244,569 anti-inflammatory agent which is an inhibitor of prosta glandin synthetase selected from the group consisting of 22 Filed: Mar. 17, 1981 the hydratropic acid derivatives; acetylsalicylic acid; the pyrazolone derivatives; the fenamic acid deriva Related U.S. Application Data tives; the aroyl-substituted pyrroles and the substituted 60) Division of Ser. No. 64,311, Aug. 6, 1979, abandoned, arylacetohydroxamic acids in a pharmaceutically ac which is a division of Ser. No. 788,453, Apr. 20, 1977, ceptable topical vehicle. Treatment of above cutaneous Pat. No. 4,185, 100, which is a continuation-in-part of disorders may also be effected by concurrent therapy Ser. No. 685,942, May 13, 1976, abandoned. using separate applications of corticosteroid and non 51) Int. Cl. ...................... A61K 31/19; A61K 31/56 steroid. (52) U.S. Cl. ..................................... 424/240; 424/317 58) Field of Search ................................ 424/317, 240 18 Claims, No Drawings 4,360,518 1 2 Ziboh, V. A. and Snyder, D. S. 1974 Naturally occur TOPICAL ANTI-NFLAMMATORY ORUG ring and synthetic inhibitors of prostaglandin synthetase THERAPY of the skin.
    [Show full text]
  • Pharmaceuticals Appendix
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ADAPALENE 106685-40-9 ABANOQUIL 90402-40-7 ADAPROLOL 101479-70-3 ABECARNIL 111841-85-1 ADEMETIONINE 17176-17-9 ABLUKAST 96566-25-5 ADENOSINE PHOSPHATE 61-19-8 ABUNIDAZOLE 91017-58-2 ADIBENDAN 100510-33-6 ACADESINE 2627-69-2 ADICILLIN 525-94-0 ACAMPROSATE 77337-76-9 ADIMOLOL 78459-19-5 ACAPRAZINE 55485-20-6 ADINAZOLAM 37115-32-5 ACARBOSE 56180-94-0 ADIPHENINE 64-95-9 ACEBROCHOL 514-50-1 ADIPIODONE 606-17-7 ACEBURIC ACID 26976-72-7 ADITEREN 56066-19-4 ACEBUTOLOL 37517-30-9 ADITOPRIME 56066-63-8 ACECAINIDE 32795-44-1 ADOSOPINE 88124-26-9 ACECARBROMAL 77-66-7 ADOZELESIN 110314-48-2 ACECLIDINE 827-61-2 ADRAFINIL 63547-13-7 ACECLOFENAC 89796-99-6 ADRENALONE 99-45-6 ACEDAPSONE 77-46-3 AFALANINE 2901-75-9 ACEDIASULFONE SODIUM 127-60-6 AFLOQUALONE 56287-74-2 ACEDOBEN 556-08-1 AFUROLOL 65776-67-2 ACEFLURANOL 80595-73-9 AGANODINE 86696-87-9 ACEFURTIAMINE 10072-48-7 AKLOMIDE 3011-89-0 ACEFYLLINE CLOFIBROL 70788-27-1
    [Show full text]
  • Pharmaceuticals As Environmental Contaminants
    PharmaceuticalsPharmaceuticals asas EnvironmentalEnvironmental Contaminants:Contaminants: anan OverviewOverview ofof thethe ScienceScience Christian G. Daughton, Ph.D. Chief, Environmental Chemistry Branch Environmental Sciences Division National Exposure Research Laboratory Office of Research and Development Environmental Protection Agency Las Vegas, Nevada 89119 [email protected] Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada Why and how do drugs contaminate the environment? What might it all mean? How do we prevent it? Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada This talk presents only a cursory overview of some of the many science issues surrounding the topic of pharmaceuticals as environmental contaminants Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada A Clarification We sometimes loosely (but incorrectly) refer to drugs, medicines, medications, or pharmaceuticals as being the substances that contaminant the environment. The actual environmental contaminants, however, are the active pharmaceutical ingredients – APIs. These terms are all often used interchangeably Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada Office of Research and Development Available: http://www.epa.gov/nerlesd1/chemistry/pharma/image/drawing.pdfNational
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 7,544,192 B2 Eaton Et Al
    US007544192B2 (12) United States Patent (10) Patent No.: US 7,544,192 B2 Eaton et al. (45) Date of Patent: Jun. 9, 2009 (54) SINUS DELIVERY OF SUSTAINED RELEASE 5,443,498 A 8, 1995 Fontaine THERAPEUTICS 5,512,055 A 4/1996 Domb et al. 5,664,567 A 9, 1997 Linder (75) Inventors: Donald J. Eaton, Woodside, CA (US); 5,693,065. A 12/1997 Rains, III Mary L. Moran, Woodside, CA (US); 5,792,100 A 8/1998 Shantha Rodney Brenneman, San Juan Capistrano, CA (US) (73) Assignee: Sinexus, Inc., Palo Alto, CA (US) (Continued) (*) Notice: Subject to any disclaimer, the term of this FOREIGN PATENT DOCUMENTS patent is extended or adjusted under 35 U.S.C. 154(b) by 992 days. WO WOO1/02024 1, 2001 (21) Appl. No.: 10/800,162 (22) Filed: Mar 12, 2004 (Continued) (65) Prior Publication Data OTHER PUBLICATIONS US 2005/OO437O6A1 Feb. 24, 2005 Hosemann, W. et al. (Mar. 2003, e-pub. Oct. 10, 2002). “Innovative s Frontal Sinus Stent Acting as a Local Drug-Releasing System.' Eur: Related U.S. Application Data Arch. Otorhinolarynolo. 260:131-134. (60) Provisional application No. 60/454,918, filed on Mar. (Continued) 14, 2003. Primary Examiner Kevin C Sirmons (51) Int. Cl Assistant Examiner Catherine NWitczak A. iM sI/00 (2006.01) (74) Attorney, Agent, or Firm Morrison & Foerster LLP (52) U.S. Cl. ........................ 604/506; 604/510; 604/514 (57) ABSTRACT (58) Field of Classification Search .............. 604/93.01, 604/891.1. 890.1, 57, 59-64, 510, 514,506; S lication file f 606/196 The invention provides biodegradable implants for treating ee application file for complete search history.
    [Show full text]
  • Cardiovascular System Drug Poster
    Cardiovascular Drugs Created by the Njardarson Group (The University of Arizona): Edon Vitaku, Elizabeth A. Ilardi, Daniel J. Mack, Monica A. Fallon, Erik B. Gerlach, Miyant’e Y. Newton, Angela N. Yazzie, Jón T. Njarðarson Ethanol Glyceryl Trinitrate Anestisine Quinidine Procaine Adrenaline Adenosine Phenylepherine Heparin Vasoxyl Sotradecol Xylocaine Pronestyl Betamethasone Catapres Cedilanide Dopamine Inversine Metaraminol Acetyldigitoxin Hydrocortisone ( Ethanol ) ( Nitroglycerin ) ( Benzocaine ) ( Quinidine ) ( Procaine ) ( Epinephrine ) ( Adenosine ) ( Phenylephrine ) ( Heparin ) ( Methoxamine ) ( Sodium Tetradecyl Sulfate ) ( Lidocaine ) ( Procainamide ) ( Betamethasone ) ( Clonidine ) ( Deslanoside ) ( Dopamine ) ( Mecamylamine ) ( Metaraminol ) ( Acetyldigitoxin ) ( Hydrocortisone ) VASOPROTECTIVE CARDIAC THERAPY VASOPROTECTIVE CARDIAC THERAPY VASOPROTECTIVE CARDIAC THERAPY CARDIAC THERAPY CARDIAC THERAPY VASOPROTECTIVE CARDIAC THERAPY VASOPROTECTIVE CARDIAC THERAPY CARDIAC THERAPY VASOPROTECTIVE ANTIHYPERTENSIVE CARDIAC THERAPY CARDIAC THERAPY ANTIHYPERTENSIVE CARDIAC THERAPY CARDIAC THERAPY VASOPROTECTIVE Approved 1700s Approved 1879 Approved 1890s Approved 1900s Approved 1903 Approved 1920s Approved 1929 Approved 1930s Approved 1935 Approved 1940s Approved 1946 Approved 1949 Approved 1950 Approved 1950s Approved 1950s Approved 1950s Approved 1950s Approved 1950s Approved 1951 Approved 1952 Approved 1952 Regitine Phenoxybenzamine Serpasol Rescinnamine Diuril Harmonyl Naturetin Hydrochlorothiazide Hydrocortamate Fastin Ismel
    [Show full text]
  • Administrative Records, Texas Department of Criminal Justice
    Consistent with the terms of the Court’s May 22, 2017 scheduling order, the record has been redacted for all information that plaintiff, Texas Department of Criminal Justice (Texas), has identified as confidential. In addition, Defendants have also redacted information that the drug’s supplier and broker have separately advised the agency they consider confidential and private, as well as information the agency itself generally treats as confidential. This information has been redacted pending final FDA’s review of confidentiality claims, and our filing of the record with these redactions does not necessarily reflect our agreement with all of the claims of confidentiality Defendants have received. Defendants explicitly reserve the right to make an independent determination regarding the proper scope of redactions at a later time. Should we identify any of Texas’s redactions that are over-broad or otherwise improper, we will work with Texas’s counsel to revise the redactions in the record. MISCELLANEOUS FDA 568 DOCUMENT#: VERSION#: DIOP PROCEDURE ~L ORO-DIOP- 2.00 FOOD & DRUG ADMINISTRATION .008 I OFFICE OF REGULATORY AFFAIRS PAGE 1 OF 4 TITLE: EFFECTIVE DATE: PROCESSING OF SODIUM THIOPENTAL ENTRIES 4/16/2012 Sections included in this document 1. Purpose 2. Scope 3. Responsibility 4. Background 5. References 6. Procedure 7. Definitions/Glossary 8. Records 9. Supporting Documents 10. Contact Information 11.Attachments Document History and Change History 1. Purpose Pending litigation, this procedure provides instructions on the handling of shipments of Sodium Thiopental by Districts and the responsibility of DIOP in the processing of Sodium Thiopental entries. Districts should disseminate this information to all pertinent staff handling these entries.
    [Show full text]
  • Pharmecovigilance and the Environmental Footprint of Pharmaceuticals Ilene S
    PharmEcovigilance and the Environmental Footprint of Pharmaceuticals Ilene S. Ruhoy, MD, PhD Touro University Nevada Institute for Environmental Medicine Henderson, NV Christian G. Daughton, PhD U.S. Environmental Protection Agency Office of Research and Development Las Vegas, NV US EPA Notice Although this work was reviewed by EPA and approved for publication, it may not necessarily reflect official Agency policy. PPCPs as Environmental Pollutants? PPCPs are a diverse group of chemicals comprising all human and veterinary drugs (available by prescription or over-the-counter, including “biologics”), diagnostic agents (e.g., X-ray contrast media), “nutraceuticals” (bioactive food supplements such as huperzine A), and other consumer chemicals, such as fragrances (e.g., musks) and sun-screen agents (e.g., 4-methylbenzylidene camphor; octocrylene); also included are “excipients” (so-called “inert” ingredients used in PPCP manufacturing and formulation; e.g., parabens). 1st National Survey Revealed Extent of PPCPs in Waterways • USGS “Reconnaissance” study in 1999-2000 was first nationwide investigation of pharmaceuticals, hormones, & other organic contaminants: – 139 streams analyzed in 30 states – 82 contaminants identified (many were pharmaceuticals) – 80% streams had 1 or more contaminant – Average 7 contaminants identified per stream • Since 1998, peer reviewed papers on PPCPs have increased from fewer than 200 per year to greater than 1,000 per year Kolpin DW,et al. "Pharmaceuticals, hormones, and other organic wastewater contaminants
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • Alimentary Tract and Metabolism Drug Poster
    Alimentary Tract and Metabolism Drugs Created by the Njardarson Group (The University of Arizona): Edon Vitaku, Elizabeth A. Ilardi, Monica A. Fallon, Erik B. Gerlach, Jack Siqueiros, Jón T. Njarðarson Magnesium Sulfate Magnesium Sulfate Calcium Chloride Papaverine Potassium Chloride Guanadine Streptomycin Azulfidine Banthine Sus-phrine Sulfite Fungizone Cortef Acetate Achromycin Pamine Pro-Banthine Cortef Acetate Meticorten Medicortelone Aristocort Decadron ( Magnesium Sulfate ) ( Magnesium Sulfate ) ( Calcium Chloride ) ( Papaverine ) ( Potassium Chloride ) ( Guanidine ) ( Streptomycin ) ( Sulfasalazine ) ( Methantheline ) ( Epinephrine ) ( Amphotericin B ) ( Hydrocortisone ) ( Tetracycline ) ( Methylscopolamine ) ( Propantheline ) ( Hydrocortisone ) ( Prednisone ) ( Prednisolone ) ( Triamcinolone ) ( Dexamethasone ) LAXATIVE MINERAL SUPPLEMENT MINERAL SUPPLEMENT GASTROINTESTINAL DISORDERS MINERAL SUPPLEMENT ANTIDIAR., ANTIINFLA. & ANTIINF. ANTIDIAR., ANTIINFLA. & ANTIINF. ANTIDIAR., ANTIINFLA. & ANTIINF. GASTROINTESTINAL DISORDERS STOMATOLOGICAL PREP ANTIDIAR., ANTIINFLA. & ANTIINF. STOMATOLOGICAL PREP STOMATOLOGICAL PREP GASTROINTESTINAL DISORDERS GASTROINTESTINAL DISORDERS ANTIDIAR., ANTIINFLA. & ANTIINF. ANTIDIAR., ANTIINFLA. & ANTIINF. ANTIDIAR., ANTIINFLA. & ANTIINF. STOMATOLOGICAL PREP STOMATOLOGICAL PREP Approved 1900s Approved 1900s Approved 1900s Approved 1915 Approved 1920s Approved 1939 Approved 1946 Approved 1950 Approved 1950s Approved 1951 Approved 1951 Approved 1953 Approved 1953 Approved 1953 Approved 1953 Approved
    [Show full text]